CVS Drops Lilly's Zepbound as Preferred Drug in Novo Win
CVS Health Corp.'s drug-benefits unit negotiated a deal to make Novo Nordisk A/S's Wegovy more widely available to its members, a blow to rival Eli Lilly & Co.'s Zepbound that was moved off the company's list of preferred drugs.
Starting July 1, Zepbound will no longer be preferred on CVS Caremark's standard formulary, while Wegovy and other anti-obesity medicines will be, according to the company. The change means that Lilly's drug may cost more to insurers or employers that opt to pay for weight-loss drugs and who use CVS Caremark to manage their prescription drug plans.
Under the new deal, 'Zepbound will be excluded' in health plans using CVS's standard drug list, CVS spokesperson David Whitrap said in an email. People in those plans on Zepbound will be able switch to Wegovy, with exceptions made for medical need on a case-by-case basis, he said.
CVS shares rose as much as 10 percent before markets opened in New York on Thursday. Novo shares were up as much as 6.5 percent in Copenhagen while Lilly fell as much as 6.7 percent in premarket trading.
Novo and Lilly have been locked in a fierce competition to dominate the obesity market, which is expected to reach $130 billion by the end of the decade. CVS Caremark's decision to place Wegovy over Zepbound could give Novo an edge as the companies fight to convince insurance companies to pay for their treatments, which cost more than $1,000 a month before rebates.
The behind-the-scenes negotiating the resulted in the change shows that competition is heating up, especially as more supply hits the market and drug plans can pit one roughly equal treatment against another. Novo is also allowing CVS to sell the drug for $499 to cash-paying customers, less than half its list price, to patients at its more than 9,000 pharmacies nationwide.
There's likely to be more haggling for similar favourable treatment in the future.
'Now that both of these GLP-1s are available in adequate supply, Caremark was able to do what PBMs do best: compete clinically similar products against one another, and choose the option that delivers the lowest net cost for our clients who choose our standard formulary,' CVS chief executive officer David Joyner said in a statement to Bloomberg News.
Health plans have complained that the popularity of drugs like Wegovy and Zepbound has led to higher costs from covering them. The agreement between CVS and Novo provides bigger discounts on Wegovy, ultimately saving the plans money, the company said.
A CVS spokesperson declined to say how much the company was saving on Wegovy.
'The cost of this therapeutic category is one of the biggest pain points for Caremark clients, and I'm proud we could be first to market with a solution that drives greater affordability.'
It is Novo's responsibility to work with players in the US health care system to connect patients with authentic Wegovy in 'a convenient and affordable way,' said Dave Moore, Novo's executive vice president of US operations, in a statement.
CVS Caremark is one of the largest pharmacy benefit managers, an industry that negotiates drug prices between insurers, pharmacies, and manufacturers. They have faced mounting criticism in Washington from lawmakers and the pharmaceutical industry for allegedly driving up prescription drug prices, a charge the industry denies.
President Donald Trump, who's said he's going to 'knock out' such intermediaries, has spoken to Lilly chief executive officer Dave Ricks about the issue.
'Every time I talk to him about drug prices, he sweet talks me,' Trump said, referring to Ricks, during a White House event they both attended on Wednesday. 'He tells me about the middlemen. By the time I leave the meetings, I say, gee, he's giving us a great bargain.'
Trump, however, has also complained about the high prices of weight-loss drugs.
CVS is the first retail pharmacy chain to sell Wegovy at a $499 cash price under a program the drugmaker announced earlier this week. Novo is also teaming up with telehealth companies including Hims & Hers Health Inc. Hims & Hers Health Inc. to sell Wegovy at the discounted rate.
Additionally, Lilly has made efforts to lower the price of Zepbound for patients whose health plans don't cover weight-loss drugs. The company is working with telehealth partners to provide broader access to the lower-cost option.
By Ike Swetlitz, Madison Muller, and Robert Langreth
Learn more:
Novo Nordisk to Sell Wegovy Through Telehealth Firms
The drug manufacturer will partner with companies like Hims & Hers and Ro amid a larger crackdown on compounded forms of its GLP-1 drugs.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
4 hours ago
- Health Line
GLP-1 Drugs Linked to Age-Related Macular Degeneration, Study Finds
GLP-1 drugs are associated with a higher risk of 'wet' age-related macular degeneration in people with type 2 diabetes, according to a new study. Researchers found that the risk substantially increased the longer people were prescribed a GLP-1 drug, particularly those containing semaglutide. GLP-1 medications like Ozempic and Wegovy have surged in popularity as weight loss treatments, but ophthalmologists say their potential risks to eye health are not well understood. GLP-1 drugs are linked to a significantly higher risk of developing neovascular or 'wet' age-related macular degeneration, according to new research. The study, conducted by researchers at the University of Toronto, found that people with type 2 diabetes who were prescribed GLP-1s were more than twice as likely to develop wet AMD as those who weren't. The study also found that the longer subjects were treated with these medications, the greater their risk of developing wet AMD. Neovascular age-related macular degeneration, commonly known as wet AMD, is the less common but more aggressive form of age-related macular degeneration, and a leading cause of irreversible vision loss among older adults in the United States. The findings, published on June 5 in JAMA Ophthalmology, suggest that doctors and patients should be aware of the potential risks, even though the chance of developing the condition remains relatively low. GLP-1 drugs, a class of blockbuster diabetes and obesity drugs sold under brand names like Ozempic and Wegovy, have surged in popularity in recent years. They offer a range of substantial benefits, including weight loss, improved blood sugar levels, and reduced cardiovascular disease risk. Despite these benefits, ophthalmologists say the impact of GLP-1 drugs on eye health is not well understood. Studies have identified an association between the medications and other eye conditions, including diabetic retinopathy and non-arteritic anterior ischemic optic neuropathy (NAION). While the findings don't establish a clear causal link between GLP-1 drugs and eye disease, experts say there's still reason for caution. 'The dose-response effect we observed — where longer GLP-1 receptor agonist exposure was associated with higher risk — strengthens the argument that this association may reflect a true biological effect rather than being due to confounding factors,' said study co-author Andrew Mihalache, MD(C), of the Temerty Faculty of Medicine at the University of Toronto, Canada. 'Seeing a graded relationship like this suggests that prolonged exposure could play a causal role in increasing risk. However, this needs to be confirmed in future studies,' he told Healthline. Long-term GLP-1 drug use may triple wet AMD risk Drawing on health records from Ontario, Canada, researchers at the University of Toronto analyzed nearly 140,000 adults with type 2 diabetes to investigate a possible link between GLP-1 use and wet AMD. The retrospective study tracked patient outcomes over a three-year period, using data collected between 2020 and 2023. Roughly one-third of participants — about 46,000 people — had been prescribed a GLP-1 drug for at least six months. The rest had not. In the vast majority of cases (97.5%), that drug was semaglutide, the active ingredient in Ozempic and Wegovy. The average participant was 66, and the cohort was almost evenly divided by sex, with females representing 46.6% of the group. On average, those who were prescribed a GLP-1 drug were more than twice as likely to be diagnosed with wet AMD. However, that number doesn't tell the full story. People who took GLP-1 drugs for longer experienced progressively greater risk. Those who had only taken their medication for 6–18 months actually had a slightly lower risk than those who didn't take the medication. However, at the 18–30 month mark, GLP-1 users' risk of developing wet AMD more than doubled compared to non-users. And those taking the drugs for 30 months or longer had more than triple the risk. 'This was definitely surprising, especially given the growing enthusiasm for GLP-1 receptor agonists for their cardiovascular and metabolic benefits. It really highlights the need for further investigation into their ocular safety profile,' first study author Reut Shor, MD, of the Department of Ophthalmology and Vision Sciences at the University of Toronto, Canada, told Healthline. Despite the increase in risk, the absolute risk of developing wet AMD was still low: 0.2% among those taking a GLP-1 and 0.1% among those who didn't. Do GLP-1 drugs harm eye health? While not definitive, the study raises further questions about the potential risks posed by GLP-1 drugs for eye health. Prior studies have also identified links between GLP-1s and other forms of eye disease in people with type 2 diabetes. In a major phase 3 semaglutide trial in 2016, researchers identified that type 2 diabetes patients taking semaglutide had a higher risk of complications of diabetic retinopathy compared to a placebo. Those findings were published in The New England Journal of Medicine. However, other studies have provided conflicting evidence. A retrospective 2024 study evaluated nearly 700 subjects with type 2 diabetes who were taking a GLP-1 drug and found no association between GLP-1s and worsening retinopathy. Also in 2024, researchers found that patients with type 2 diabetes who were prescribed semaglutide were at greater risk of NAION compared to those who weren't. NAION is a condition that causes sudden blindness, typically just in one eye, due to a lack of blood flow to the optic nerve. The mechanism for why GLP-1 drug use may lead to wet AMD is not well established, but a predominant theory is that lowering blood sugar rapidly leads to a lack of oxygen in the retina. 'When you make the retina more hypoxic, which is what the GLP-1s do, it basically pushes it further over the threshold, causing more abnormal blood vessels to grow,' said Linda Lam, MD, MBA, an ophthalmologist with Keck Medicine of USC, who wasn't involved in the research. Abnormal blood vessel growth in the eye is the hallmark of wet AMD. While GLP-1s offer many health benefits, eye disease risk must be considered in some populations, Lam told Healthline. 'In this particular group of patients who are older, who are diabetics, I really would caution against the extended use of GLP-1s,' she said. Lam reiterated the importance of annual eye exams for the general population, but in particular for those with diabetes, to identify and diagnose eye disease early on. People with type 2 diabetes, especially those taking a GLP-1 drug, should be aware of the signs and symptoms of vision loss and consult with their doctor immediately. These include:
Yahoo
8 hours ago
- Yahoo
Revelation-Backed Omada Health Jumps After $150 Million IPO
(Bloomberg) -- Omada Health Inc. shares ended their debut trading day exactly where they started after the digital health-care company raised $150 million in its initial public offering. Next Stop: Rancho Cucamonga! ICE Moves to DNA-Test Families Targeted for Deportation with New Contract Where Public Transit Systems Are Bouncing Back Around the World US Housing Agency Vulnerable to Fraud After DOGE Cuts, Documents Warn Trump Said He Fired the National Portrait Gallery Director. She's Still There. The stock climbed 21% to close at $23 on Friday in New York — the same price it opened at — higher than its IPO price of $19 per share. The stock had jumped as much as 49% during the the trading session. The San Francisco-based company sold 7.9 million shares at $19 each after offering them at $18 to $20 apiece, according to its filings with the US Securities and Exchange Commission. The trading gives Omada a market value of $1.3 billion based on the number of outstanding shares listed in its filings. The IPO adds to the growing pace of US first-time share sales this year, which have raised around $24.9 billion so far, versus $17.6 billion in the same period last year, according to data compiled by Bloomberg. Shares of health-care upstarts that went public on US exchanges this year are also up by a weighted average of roughly 18%, according to Bloomberg calculations. An IPO last month for digital physical therapy provider Hinge Health Inc. — a competitor to Omada — raised $503 million, and shares have risen about 19% since its debut. Omada's offering closed with orders for more than 15 times the shares available, with allocations going to a highly concentrated group of investors, Bloomberg News has reported. Virtual Care Founded in 2011, Omada provides virtual care in between doctor's visits to help people manage chronic conditions including diabetes and prediabetes, obesity, hypertension and musculoskeletal conditions, according to the filing. Users track metrics including weight, blood pressure and blood glucose values to the company's platform, which includes a mobile app. Unlike other digital health firms, Omada doesn't offer GLP-1 weight loss drugs, the filing shows. Instead it has programs to support people using them, including coaching and nutrition guidance, to manage muscle loss and stop the weight from returning when they cease taking the medication, according to the filing. About 50,000 of Omada's 679,000 members are on GLP-1s, co-founder and Chief Executive Officer Sean Duffy said in an interview with Bloomberg News. It's a relatively new business for the company that has expanded in the past year as part of its partnership with Cigna Group's Express Scripts unit, he said. 'For support, especially in chronic disease, it's very helpful that someone feels they are not just doing this for themselves but for someone else - to have someone rooting for you in your corner is really important for outcomes,' Duffy said. Omada is using AI to automate the virtual care it provides to chronic disease sufferers, though the services are 'human-led,' he said. 'Our members tell us they want a person and I am yet to see anyone that feels accountable to ChatGPT,' Duffy said. Omada has over 2,000 customers including employers and health systems, and more than 679,000 total members enrolled in one or more programs, according to the filing. Largest Shareholder Revelation Partners is Omada's largest shareholder, beneficially owning 10.9% of the company before the offering, according to the filing. USVP has 9.9% of the shares, Andreessen Horowitz has 9.6% and FMR has 9.3%, the filing shows. Omada was valued at more than $1 billion in a 2022 funding round led by Fidelity Management & Research Co., it said in a statement at the time. The company had a net loss of $9.4 million on revenue of close to $55 million in the first three months of 2025, compared with a net loss of nearly $19 million on revenue of $35.1 million in the same period a year earlier, the filing shows. The offering was led by Morgan Stanley, Goldman Sachs Group Inc. and JPMorgan Chase & Co., the filing shows. The company's shares trade on the Nasdaq Global Market under the symbol OMDA. (Updates with closing prices.) Cavs Owner Dan Gilbert Wants to Donate His Billions—and Walk Again The SEC Pinned Its Hack on a Few Hapless Day Traders. The Full Story Is Far More Troubling YouTube Is Swallowing TV Whole, and It's Coming for the Sitcom Is Elon Musk's Political Capital Spent? Trump Considers Deporting Migrants to Rwanda After the UK Decides Not To ©2025 Bloomberg L.P.
Fast Company
8 hours ago
- Fast Company
Rite Aid store closures update: Latest list includes doomed locations in California, Washington, and Oregon
The list of Rite Aid store closures continues to grow. As the drugstore chain prepares to sell off its remaining assets in the wake of filing for bankruptcy for a second time, the total number of locations marked for closure in court documents as of this week is at least 497 nationwide. The chain will eventually sell or shutter all of its 1,277 pharmacies as it winds down operations. According to a court filing on Thursday, the latest list includes 25 additional locations in Ohio, California, Oregon, and Washington state. Bids on Rite Aid's remaining assets are due on June 18. Pharmacy assets already sold Rite Aid has already reached agreements to offload some of its assets—notably, its valuable prescription files—to CVS, the country's largest pharmacy chain; Walgreens; and the Albertsons and Kroger grocery chains. As Fast Company previously reported, CVS agreed to buy prescription files for 625 of those pharmacies and take over 64 brick-and-mortar Rite Aid locations in Idaho, Washington, Oregon, home to many of the latest closures. Rite Aid's mass closures present particular challenges for customers in rural areas who rely on the chain for their medications, sparking concerns about pharmacy deserts. The broader wind-down has left many remaining locations with empty shelves as products run out. Fast Company has reached out to Rite Aid for additional information about the timeline of the closures. Here's what to know. Which Rite Aid stores are among the latest closings? According to this week's filing, the following 25 locations are set to close and may already be in the process of doing so. CALIFORNIA 2505 Mt Vernon Avenue, Bakersfield, CA 93306 602 Williams Road, Salinas, CA 93905 4322 South Figueroa Street, Los Angeles, CA 90037 1560 Sycamore Avenue, Hercules, CA 94547 32121 Camino Capistrano, San Juan Capistrano, CA 92675 1501 West Main Street, El Centro, CA 92243 10823 Zelzah Avenue Bldg D, Granada Hills, CA 91344 19035 Bear Valley Road, Apple Valley, CA 92308 7025 El Camino Real, Atascadero, CA 93422 24330 El Toro Road, Laguna Woods, CA 92637 295 West Main Street, Woodland, CA 95695 1735 E Walnut Avenue, Visalia, CA 93292 300 North Canon Drive, Beverly Hills, CA 90210 OREGON 2021 NW 185th Avenue, Hillsboro, OR 97124 681 Lancaster Drive NE, Salem, OR 97301 1970 Echo Hollow Road, Eugene, OR 97402 1560 Coburg Road, Eugene, OR 97401 Ohio 1955 Cleveland Road, Wooster OH 44691 WASHINGTON 2131 SW 336th Street, Federal Way, WA 98023 10407 SE 256th Street, Kent, WA 98030 5700 100th Street SW Ste 100, Lakewood, WA 98499 3116 NE Sunset Boulevard, Renton, WA 98056 140th Avenue SE, Renton, WA 98058 196th Street SW, Lynnwood, WA 98036 2860 NW Bucklin Hill Road, Silverdale, WA 98383 Where can I find the full list of Rite Aid closures? Previous filings have revealed closures as noted below: May 5: 47 initial locations May 9: 68 additional locations May 16: 95 additional locations May 23: 151 additional locations May 30: 111 additional locations How did Rite Aid get here? Rite Aid's Chapter 11 bankruptcy filings come less than one year are a similar filing in 2023. Like many drugstore chains, including CVS and Walgreens, Rite Aid has struggled with online competition from Amazon and other retailers and decreased profits from prescription drugs due to lower reimbursement rates.
